All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings.
These reports are called 13F reports. However, the filings are required
the following quarter
from the reporting period,
which means that by the time the filing is made (and we see them), the information could be five months old.
For funds
with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover,
the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions
are identified in the table. However, they are not required to report short positions.
Click the link icon to see the full transaction history.
Upgrade
to unlock premium data and export to Excel 
.
| Security |
Imputed
Share Price |
Prev
Shares |
Current
Shares |
Change
(Percent) |
Prev Value
(USD x1000) |
Current Value
(USD x1000) |
Change
(Percent) |
|---|
| CDXS / Codexis, Inc.
|
|
|
|
|
|
|
|
| SLRN / Acelyrin, Inc.
|
|
|
|
|
|
|
|
| LQDA / Liquidia Corporation
|
|
|
|
|
|
|
|
| PTGX / Protagonist Therapeutics, Inc.
|
|
|
|
|
|
|
|
| OCUL / Ocular Therapeutix, Inc.
|
|
|
|
|
|
|
|
| XOMA / XOMA Royalty Corporation
|
|
|
|
|
|
|
|
| HROW / Harrow, Inc.
|
|
|
|
|
|
|
|
| IOVA / Iovance Biotherapeutics, Inc.
|
|
|
|
|
|
|
|
| JSPR / Jasper Therapeutics, Inc.
|
|
|
|
|
|
|
|
| URGN / UroGen Pharma Ltd.
|
|
|
|
|
|
|
|
| PCVX / Vaxcyte, Inc.
|
|
|
|
|
|
|
|
| RVNC / Revance Therapeutics, Inc.
|
|
|
|
|
|
|
|
| NUVL / Nuvalent, Inc.
|
|
|
|
|
|
|
|
| BDSX / Biodesix, Inc.
|
|
|
|
|
|
|
|
| US38341PAA03 / Gossamer Bio Inc
|
|
|
|
|
|
|
|
| ZNTL / Zentalis Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| RYTM / Rhythm Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| ETON / Eton Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| LRMR / Larimar Therapeutics, Inc.
|
|
|
|
|
|
|
|
| SVRA / Savara Inc.
|
|
|
|
|
|
|
|
| LYEL / Lyell Immunopharma, Inc.
|
|
|
|
|
|
|
|
| PMVP / PMV Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| US48576UAA43 / Karyopharm Therapeutics Inc
|
|
|
|
|
|
|
|
| KPTI / Karyopharm Therapeutics Inc.
|
|
|
|
|
|
|
|
| ALGS / Aligos Therapeutics, Inc.
|
|
|
|
|
|
|
|
| FDMT / 4D Molecular Therapeutics, Inc.
|
|
|
|
|
|
|
|
| LXRX / Lexicon Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| NAMS / NewAmsterdam Pharma Company N.V.
|
|
|
|
|
|
|
|
| SYRS / Syros Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| GOSS / Gossamer Bio, Inc.
|
|
|
|
|
|
|
|
| RPHM / Reneo Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| MOR / MorphoSys AG - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| NYXH / Nyxoah SA
|
|
|
|
|
|
|
|
| RPTX / Repare Therapeutics Inc.
|
|
|
|
|
|
|
|
| PGEN / Precigen, Inc.
|
|
|
|
|
|
|
|
| CRNX / Crinetics Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| CMPX / Compass Therapeutics, Inc.
|
|
|
|
|
|
|
|
| GKOS / Glaukos Corporation
|
|
|
|
|
|
|
|
| TARA / Protara Therapeutics, Inc.
|
|
|
|
|
|
|
|
| DSGN / Design Therapeutics, Inc.
|
|
|
|
|
|
|
|
| CYTK / Cytokinetics, Incorporated
|
|
|
|
|
|
|
|
| NTLA / Intellia Therapeutics, Inc.
|
|
|
|
|
|
|
|
| APLT / Applied Therapeutics, Inc.
|
|
|
|
|
|
|
|
| VSTM / Verastem, Inc.
|
|
|
|
|
|
|
|
| RGLS / Regulus Therapeutics Inc.
|
|
|
|
|
|
|
|
| ALLK / Allakos Inc.
|
|
|
|
|
|
|
|
| AVTE / Aerovate Therapeutics, Inc.
|
|
|
|
|
|
|
|
| CPRX / Catalyst Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| KROS / Keros Therapeutics, Inc.
|
|
|
|
|
|
|
|
| FULC / Fulcrum Therapeutics, Inc.
|
|
|
|
|
|
|
|
| RLMD / Relmada Therapeutics, Inc.
|
|
|
|
|
|
|
|
| ARVN / Arvinas, Inc.
|
|
|
|
|
|
|
|
| CRGX / CARGO Therapeutics, Inc.
|
|
|
|
|
|
|
|
| IBIO / iBio, Inc.
|
|
|
|
|
|
|
|
| EWTX / Edgewise Therapeutics, Inc.
|
|
|
|
|
|
|
|
| NRIX / Nurix Therapeutics, Inc.
|
|
|
|
|
|
|
|
| VTYX / Ventyx Biosciences, Inc.
|
|
|
|
|
|
|
|
| TRVI / Trevi Therapeutics, Inc.
|
|
|
|
|
|
|
|
| TGTX / TG Therapeutics, Inc.
|
|
|
|
|
|
|
|
| ABCL / AbCellera Biologics Inc.
|
|
|
|
|
|
|
|
| IMNM / Immunome, Inc.
|
|
|
|
|
|
|
|
| CNTX / Context Therapeutics Inc.
|
|
|
|
|
|
|
|
